NCT05145010
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Enrolling by Invitation
PHASE2Ages 3–18InterventionalTreatmentQED Therapeutics, a BridgeBio company
~300 participants
Updated 2025-10-31 on ClinicalTrials.gov
What's tested:Infigratinib
At a glance
Recruiting sites
0 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment emergent adverse events (TEAE) and serious TEAE
Measured over 10 years
+1 more outcome measured
Conditions
Where it's being run
31 sites across 20 statesUnited Kingdom6
France3
Ontario2
Italy2
Norway2
Spain2
California1
Colorado1
Study leadership
- QED Therapeutics SVP, Clinical Development · STUDY_DIRECTOR · QED Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of treatment emergent adverse events (TEAE) and serious TEAE10 years
- Changes over time in height Z-score in relation to ACH and non-ACH growth charts10 years